Literature DB >> 15262879

Rosuvastatin (Crestor) and rhabdomyolysis.

Eric Wooltorton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262879      PMCID: PMC450358          DOI: 10.1503/cmaj.1041051

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  Cerivastatin and reports of fatal rhabdomyolysis.

Authors:  Judy A Staffa; Jennie Chang; Lanh Green
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

Review 2.  Statin-associated myopathy.

Authors:  Paul D Thompson; Priscilla Clarkson; Richard H Karas
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

Review 3.  Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.

Authors:  H Bryan Brewer
Journal:  Am J Cardiol       Date:  2003-08-21       Impact factor: 2.778

  3 in total
  4 in total

1.  Rhabdomyolysis-induced compartment syndrome secondary to atorvastatin and strenuous exercise.

Authors:  Louise Dunphy; Rossel Morhij; Sarah Tucker
Journal:  BMJ Case Rep       Date:  2017-03-16

2.  Severe obstructive sleep apnea after cerivastatin therapy: a case report.

Authors:  Matthew R Ebben; Nitin K Sethi; Arthur J Spielman
Journal:  J Clin Sleep Med       Date:  2008-06-15       Impact factor: 4.062

3.  Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study.

Authors:  Jamie L Fleet; Eric McArthur; Aakil Patel; Matthew A Weir; Manuel Montero-Odasso; Amit X Garg
Journal:  CMAJ       Date:  2019-09-16       Impact factor: 8.262

4.  Daptomycin in combination with rosuvastatin induced blood creatine phosphokinase elevation.

Authors:  Mefküre Durmuş; Ömer Faruk Bahçecioğlu; Selim Gök
Journal:  Eur J Hosp Pharm       Date:  2020-03-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.